Pembrolizumab berahyaluronidase alfa
Merck & Co., Inc. MRK · Non-small Cell Lung Cancer; Hematologic Malignancies; Lung Cancer; Solid Tumors
Key figures
Next catalyst
None scheduled
Only dates with a source are listed
Phase
Phase 3
Not recorded
Linked trials
3
From ClinicalTrials.gov
Latest FDA action
None on record
From Drugs@FDA
Recalls, shortages, patents and EU status at a glance
Key information
- Sponsor
- Merck & Co., Inc. MRK Source: Company record for Merck & Co., Inc. (opens in a new tab)
- Indications
- Non-small Cell Lung Cancer; Hematologic Malignancies; Lung Cancer; Solid Tumors Source: Conditions from ClinicalTrials.gov (opens in a new tab)
- Designations
- None recorded
- Next catalyst
- None scheduled
Development timeline
- Preclinical Completed
- Phase 1 Completed
- Phase 2 Completed
- Phase 3 Current stageFirst trial start 21 Aug 20183 linked trials
- Filed Not yet
- Approved Not yet
Overview
- Mechanism
- Not recorded
- Route
- Not recorded
- Modality
- Not recorded
- Specialties
- Not recorded
Overview text is written by HealthTrade editors.
Key dates
No catalysts yet. Editors add each date together with its source.
FDA designations
No FDA designations are on record for Pembrolizumab berahyaluronidase alfa. Editors add each one with its source.
Filed application
No filed application is on record for Pembrolizumab berahyaluronidase alfa. Approvals are listed under FDA actions.
FDA advisory committees
No FDA advisory committee meetings are on record for Pembrolizumab berahyaluronidase alfa.
Clinical trials
| Trial | Title | Phase | Status | Enrollment | Primary completion | Results posted |
|---|---|---|---|---|---|---|
| NCT07190248ClinicalTrials.gov record for NCT07190248 (opens in a new tab) | A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) | Phase 3 | Recruiting | 675 (estimated) | 7 Dec 2029 (estimated) | No |
| NCT06698042ClinicalTrials.gov record for NCT06698042 (opens in a new tab) | A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84) | Phase 3 | Active, not recruiting | 67 (actual) | 12 Mar 2026 (actual) | No |
| NCT03486873ClinicalTrials.gov record for NCT03486873 (opens in a new tab) | Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) | Phase 3 | Recruiting | 3,500 (estimated) | 4 Aug 2043 (estimated) | No |
Publications listing NCT03486873 (2), newest first
Citations from PubMed, U.S. National Library of Medicine; abstracts are not stored. A publication lists this study’s NCT number and may be a review that cites many studies. | ||||||
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Posted results are shown as ClinicalTrials.gov prints them; results from company and journal sources are entered by editors and listed separately. Full result tables are on ClinicalTrials.gov.
Trial quality
About CT-VCALoading trial quality…
FDA actions
No FDA approvals on record for this drug.
FDA recalls load here.
FDA drug shortages load here.
Orange Book patents load here.
FAERS adverse event counts load here.
Papers and preprints load here.
Community discussion loads here.
EU status (EMA)
EMA's medicines data lists no human medicine with the same active substance as Pembrolizumab berahyaluronidase alfa.
Source: European Medicines Agency (EMA), medicines data download.
Related news
No recent headlines mention this drug.
Sources
- ClinicalTrials.gov NCT03486873 (opens in a new tab) Licence: public-domain. Official registry record this listing came from
- ClinicalTrials.gov NCT07190248 (opens in a new tab) Licence: public-domain. Official registry record this listing came from
- ClinicalTrials.gov NCT06698042 (opens in a new tab) Licence: public-domain. Official registry record this listing came from
Record updated .
Dates come from company and FDA disclosures and can change. Nothing on this page is investment advice.